Bladder & Urothelial Cancer

Quick Answer

Bladder cancer is usually urothelial (transitional-cell) carcinoma, driven overwhelmingly by smoking. Nuclear medicine's value is chiefly in muscle-invasive/metastatic disease: FDG-PET/CT detects distant metastases and nodal disease and assesses treatment response — but it is limited for the primary tumor and pelvic nodes because intense urinary FDG excretion obscures the bladder (mitigated with hydration, a diuretic, and delayed/post-void imaging). Cystoscopy and CT urography remain primary for local disease.

Definition

Bladder cancer is a malignancy of the urothelium lining the bladder (and, in "upper-tract" disease, the ureters/renal pelvis). The dominant histology is urothelial (transitional-cell) carcinoma; squamous (schistosomiasis-associated) and adenocarcinoma are less common. It is clinically divided into non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) disease.

Synonyms

Urothelial carcinoma; transitional-cell carcinoma (TCC); bladder carcinoma; upper-tract urothelial carcinoma (UTUC).

Epidemiology

Bladder cancer is common, with a strong male predominance and peak incidence in older adults. Smoking is the dominant risk factor; occupational and schistosomal exposures matter regionally. Most present as non-muscle-invasive disease.

Etiology & Risk Factors

• Smoking (the leading cause).
• Occupational aromatic amines (dye, rubber, leather industries).
• Chronic irritation/infection — schistosomiasis (squamous-cell carcinoma), indwelling catheters, stones.
• Cyclophosphamide and prior pelvic radiation; Lynch syndrome (upper-tract).

Pathophysiology

Two molecular tracks broadly correspond to clinical behavior: NMIBC (papillary, FGFR3-driven, frequently recurring but often low-grade) and MIBC (flat/high-grade, TP53/RB1-altered, invasion and metastatic potential). A field effect underlies multifocality and upper-tract involvement. Metastatic spread is to pelvic/retroperitoneal nodes, lung, liver, and bone.

Genetics & Molecular Biology

• FGFR3 alterations (NMIBC / luminal) — targeted by erdafitinib.
• TP53, RB1 (MIBC / basal), chromatin-remodeling genes.
• Nectin-4 expression — target of the antibody–drug conjugate enfortumab vedotin.
• PD-L1 and tumor mutational burden — immunotherapy relevance.

Histopathology

Urothelial carcinoma (papillary or flat, graded low/high), with squamous and glandular differentiation in subsets; schistosomiasis-associated squamous-cell carcinoma in endemic regions. Muscularis-propria invasion defines MIBC.

Clinical Presentation

Painless gross hematuria is the classic presentation; irritative voiding symptoms occur. Advanced disease presents with obstructive uropathy, pelvic mass, or metastatic symptoms.

Laboratory Findings

Urine cytology and cystoscopic biopsy are diagnostic; urinary tumor-marker assays are adjuncts. No specific serum marker; molecular profiling (FGFR3, nectin-4, PD-L1) guides advanced-disease therapy.

Imaging Findings by Modality

• Cystoscopy + TURBT: the diagnostic and local-staging standard.
• CT urography / MRI: upper-tract evaluation and local/nodal staging (multiparametric MRI with VI-RADS for muscle invasion).
• FDG-PET/CT: distant metastasis and nodal detection and response assessment in MIBC — with technique to overcome bladder activity.
• Bone scan: osseous metastases (adjunct).

Radiopharmaceutical Uptake Mechanisms

FDG reflects tumor glucose metabolism — bladder cancer is generally avid — but FDG is renally excreted, so intense urinary bladder activity obscures the primary and adjacent pelvic nodes. Forced hydration, a loop diuretic (furosemide), bladder irrigation/catheterization, and delayed post-void imaging improve pelvic evaluation.

Typical PET Tracers

Typical SPECT Tracers

• Bone scan for osseous metastases (adjunct).

Therapy Indications

• NMIBC: transurethral resection (TURBT) + intravesical BCG or chemotherapy; surveillance.
• MIBC: radical cystectomy (with neoadjuvant platinum chemotherapy) or bladder-preserving chemoradiation.
• Advanced/metastatic: platinum chemotherapy, immune-checkpoint inhibitors, enfortumab vedotin (nectin-4 ADC), erdafitinib (FGFR-altered), and antibody–drug-conjugate combinations.

Theranostics

There is no established radioligand therapy in bladder cancer; the molecularly targeted agents are antibody–drug conjugates (nectin-4) and FGFR inhibitors rather than radionuclides. Investigational molecular imaging of these targets is an emerging research direction; nuclear medicine's current role is FDG staging/response in advanced disease.

Differential Diagnosis (of pelvic FDG findings)

• Physiologic urinary/bladder activity obscuring or mimicking disease (the central pitfall).
• Post-instrumentation/BCG cystitis and inflammatory uptake.
• Reactive pelvic nodes vs nodal metastasis; benign prostatic/uterine activity.

Reporting Checklist

• State the pelvic-clearance technique used (hydration, diuretic, post-void/delayed) and any residual bladder-activity limitation.
• Emphasize distant and nodal disease and response; defer local T-staging to cystoscopy/MRI.
• Distinguish post-BCG/inflammatory uptake from tumor.

Prognosis

Prognosis hinges on muscle invasion and stage: NMIBC is often chronic-relapsing but rarely lethal, while MIBC and metastatic disease carry a worse prognosis. Molecular subtype and response to neoadjuvant chemotherapy/immunotherapy refine outcomes; nodal and distant disease (well detected by FDG) are key adverse factors.

Board Pearls

FDG-PET/CT is most valuable for distant metastasis, nodal disease, and response in muscle-invasive/metastatic bladder cancer — but it is limited for the primary and pelvic nodes because urinary FDG excretion obscures the bladder. Cystoscopy and CT urography/MRI remain primary for local disease.

Overcome the urinary-activity problem with forced hydration, a loop diuretic, bladder irrigation/catheterization, and delayed post-void imaging — and distinguish post-BCG/inflammatory cystitis uptake from tumor.

Biology drives modern therapy targets rather than radioligands: FGFR3 (erdafitinib) and nectin-4 (enfortumab vedotin) are the actionable molecules, plus immunotherapy — so bladder cancer's "targeted" story is ADC/TKI, not (yet) radionuclide theranostics. Smoking is the dominant cause; schistosomiasis drives squamous-cell carcinoma regionally.

Related Pages

• Tracer: FDG (urinary-excretion pitfall, pelvic technique).
• Related GU: renal cell carcinoma, renal scintigraphy (obstruction from pelvic disease).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A pelvic-clearance technique graphic (hydration → diuretic → post-void/delayed imaging).
• An NMIBC vs MIBC molecular/clinical two-track diagram.
• A targeted-therapy map (FGFR3/erdafitinib, nectin-4/enfortumab).

Common Pitfalls

• Even with a diuretic protocol, residual layering urine or focal Foley-catheter activity at the bladder base can hide the primary or mimic a lesion — the bladder primary is unreliable on PET regardless of technique.
• Post-chemoradiation inflammatory uptake in the bladder wall and pelvic nodes mimics residual or recurrent tumor — allow an adequate treatment-to-scan interval before response assessment.
• Small or normal-sized nodal metastases fall below FDG resolution (false negative), so a negative PET does not exclude nodal disease; conversely, reactive nodes can be falsely positive.
• Ureteral/collecting-system urinary stasis or a bladder diverticulum retaining excreted tracer can simulate a mass — correlate with CT.

Self-Check (Board-Style)